CO2022017670A2 - Antibodies against sars-cov-2 - Google Patents

Antibodies against sars-cov-2

Info

Publication number
CO2022017670A2
CO2022017670A2 CONC2022/0017670A CO2022017670A CO2022017670A2 CO 2022017670 A2 CO2022017670 A2 CO 2022017670A2 CO 2022017670 A CO2022017670 A CO 2022017670A CO 2022017670 A2 CO2022017670 A2 CO 2022017670A2
Authority
CO
Colombia
Prior art keywords
cov
sars
antigen
antibodies against
against sars
Prior art date
Application number
CONC2022/0017670A
Other languages
Spanish (es)
Inventor
Davide Corti
Martina Beltramello
Elisabetta Cameroni
Dora Pinto
Gyorgy Snell
Florian A Lempp
Amalio Telenti
Matteo Samuele Pizzuto
Marco Anna De
Nadine Czudnochowski
Colin Havenar-Daughton
Fabrizia Zatta
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of CO2022017670A2 publication Critical patent/CO2022017670A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se pueden unir a un antígeno de SARS-CoV-2 y, en ciertas modalidades, son capaces de neutralizar de manera potente una infección por SARS-CoV-2. También se proporcionan polinucleótidos que codifican para anticuerpos y fragmentos de unión a antígeno, vectores, células hospedadoras, y composiciones y usos relacionados, incluyendo para prevenir, tratar, y diagnosticar una infección por SARS-CoV-2 u otro coronavirus.The present disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of potently neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides encoding antibodies and antigen-binding fragments, vectors, host cells, and related compositions and uses, including for preventing, treating, and diagnosing SARS-CoV-2 or other coronavirus infection.

CONC2022/0017670A 2020-05-08 2022-12-06 Antibodies against sars-cov-2 CO2022017670A2 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063022392P 2020-05-08 2020-05-08
US202063024372P 2020-05-13 2020-05-13
US202063027814P 2020-05-20 2020-05-20
US202063029338P 2020-05-22 2020-05-22
US202063031286P 2020-05-28 2020-05-28
US202063033045P 2020-06-01 2020-06-01
US202063036683P 2020-06-09 2020-06-09
US202063039939P 2020-06-16 2020-06-16
US202063046465P 2020-06-30 2020-06-30
US202063057767P 2020-07-28 2020-07-28
US202063090667P 2020-10-12 2020-10-12
US202063113450P 2020-11-13 2020-11-13
US202163153784P 2021-02-25 2021-02-25
US202163170368P 2021-04-02 2021-04-02
PCT/US2021/031442 WO2021226560A1 (en) 2020-05-08 2021-05-07 Antibodies against sars-cov-2

Publications (1)

Publication Number Publication Date
CO2022017670A2 true CO2022017670A2 (en) 2023-03-07

Family

ID=76250434

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0017670A CO2022017670A2 (en) 2020-05-08 2022-12-06 Antibodies against sars-cov-2

Country Status (11)

Country Link
EP (1) EP4146690A1 (en)
JP (1) JP2023525039A (en)
KR (1) KR20230010676A (en)
AU (1) AU2021268361A1 (en)
BR (1) BR112022022523A2 (en)
CA (1) CA3177169A1 (en)
CL (1) CL2022003085A1 (en)
CO (1) CO2022017670A2 (en)
IL (1) IL297988A (en)
MX (1) MX2022013886A (en)
WO (1) WO2021226560A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231031T1 (en) * 2020-02-26 2023-12-22 Vir Biotechnology, Inc. Antibodies against sars-cov-2
JP7116256B1 (en) 2020-04-02 2022-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Anti-SARS-COV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
CR20220660A (en) 2020-06-03 2023-02-17 Regeneron Pharma METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting sars-cov-2
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
CA3225575A1 (en) * 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023201256A1 (en) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
US11993644B2 (en) 2022-05-06 2024-05-28 Generate Biomedicines, Inc. Antigen binding molecules targeting SARS-CoV-2
US20230365658A1 (en) * 2022-05-16 2023-11-16 Lawrence Livermore National Security, Llc REPAIRED THERAPEUTIC AND PROPHYLACTIC ANTIBODIES AGAINST SARS-CoV-2 VARIANTS
WO2023235827A2 (en) * 2022-06-03 2023-12-07 The Rockefeller University Coronavirus-inhibiting antibodies
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2024081269A1 (en) * 2022-10-10 2024-04-18 Dixit Rohan Therapeutic combinations and methods to treat long covid
WO2024102674A1 (en) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Antigen binding molecules targeting sars-cov-2
CN117362421A (en) * 2022-12-02 2024-01-09 中国科学院微生物研究所 Broad-spectrum monoclonal antibody for novel coronavirus RBD, preparation method and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
ES2923641T3 (en) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Immunoglobulin with Fabs in tandem and uses thereof
WO2016181357A1 (en) 2015-05-13 2016-11-17 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Antibodies with functional domains in the elbow region
JP7387611B2 (en) 2017-09-22 2023-11-28 ウーシー バイオロジクス アイルランド リミテッド Novel bispecific polypeptide complex

Also Published As

Publication number Publication date
KR20230010676A (en) 2023-01-19
EP4146690A1 (en) 2023-03-15
JP2023525039A (en) 2023-06-14
WO2021226560A1 (en) 2021-11-11
BR112022022523A2 (en) 2023-01-10
MX2022013886A (en) 2022-11-30
CA3177169A1 (en) 2021-11-11
AU2021268361A1 (en) 2022-12-08
IL297988A (en) 2023-01-01
CL2022003085A1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
CO2022017670A2 (en) Antibodies against sars-cov-2
CO2022013525A2 (en) Antibodies against sars-cov-2 and methods of using them
BR112022015374A2 (en) ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USE THEREOF
UY39118A (en) ANTIBODIES AGAINST SARS-Cov-2 (SARS2, COVID-19)
CL2023000705A1 (en) Antibodies against anti-sars-cov-2 spike glycoprotein and antigen-binding fragments
CL2021002994A1 (en) Novel antibodies that specifically bind to Zika virus epitopes and their uses. (divisional application no. 201900067)
CO2020000214A2 (en) Agonist antibodies that bind to human cd137 and their uses
BR112022020706A2 (en) ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF THEIR USE
CO7160026A2 (en) Mycoplasma hyopneumoniae vaccine
ECSP22094536A (en) ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF SELECTION AND USE THEREOF
CO2020013089A2 (en) Antibodies against mica and / or micb and their uses
CO2021009693A2 (en) Anti-il2 gamma receptor antigen-binding proteins
BR112023004351A2 (en) METHOD TO TREAT FOLLICULAR LYMPHOMA IN A HUMAN SUBJECT
CO2023006684A2 (en) Antibodies against sars-cov-2 and their uses
CO2022002573A2 (en) Antibodies against ilt2 and their use
CO2021011944A2 (en) CD33 Antibodies and Methods of Using Them to Treat Cancer
AR122674A1 (en) ANTIBODIES BINDING TO CD3 AND CD19
CO2023002375A2 (en) Antibodies against ilt2 and use thereof
CO2023002034A2 (en) Multi-specific antigen-binding molecules against hiv and methods of use
DOP2022000218A (en) ANTI-PHF-TAU ANTIBODIES AND THEIR USES
CO2023007527A2 (en) Broadly neutralizing antibodies against influenza neuraminidase
CO2023012639A2 (en) Methods for the treatment of thyroid eye disease
BR112021010634A2 (en) Antiperiostin antibodies and their uses
ECSP22004680A (en) ANTI-ANGPT2 ANTIBODIES
AR125231A2 (en) HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS